Scientific and clinical resources for healthcare professionals
Inventiva Medical Affairs
Inventiva Medical Affairs supports scientific exchange and provides resources for healthcare professionals, researchers, and qualified stakeholders interested in MASH and lanifibranor.
About MASH
Metabolic dysfunction-associated steatohepatitis is a progressive liver disease associated with metabolic risk factors and significant long-term complications.
MASH can lead to fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. It is also closely associated with cardiometabolic disease, including obesity, type 2 diabetes, and dyslipidemia.
Medical Affairs resources are intended to support balanced scientific exchange and help qualified audiences understand the evolving clinical landscape.
About Lanifibranor
Lanifibranor is an investigational pan-PPAR agonist being evaluated for the treatment of MASH.
Lanifibranor is designed to activate all three PPAR isoforms: alpha, delta, and gamma. This multimodal approach is intended to target pathways involved in inflammation, fibrosis, and metabolic dysfunction.
The safety and efficacy of lanifibranor have not been established by regulatory authorities. It remains an investigational therapy.
Lanifibranor is currently being studied in a Phase 3 clinical development program.
EASL2026: Lanifibranor-Induced Histological and Cardiometabolic Improvements in MASH Are Independent of Weight Change and Associated With Adiponectin Induction
EASL 2026: Ultrastructural Assessment of Liver Sinusoidal Endothelial Cell Capillarisation in Metabolic Dysfunction-Associated Steatotic Liver Disease and Its Modulation by Lanifibranor
MASH-TAG 2026: Comparative Modulation of Adiponectin Across Select Therapeutics in Clinical Development for MASH with Fibrosis Identifies Lanifibranor as a Differentiated Metabolic Modulator
Publication in Clinical Gastroenterology and Hepatology: Biomarkers of histological response in patients with metabolic dysfunction-associated steatohepatitis treated with lanifibranor.
Publication in Biomedicine & Pharmacotherapy: The pan-PPAR agonist lanifibranor reduces portal pressure independent of fibrosis reduction through the splanchnic vasculature.
Publication in Journal of Hepatology: Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with type 2 diabetes and MASLD.
AASLD 2024: Combination therapy of lanifibranor with empagliflozin: metabolic improvement in patients with Metabolic Dysfunction-Associated Steatohepatitis and Type-2 Diabetes
Publication in Diabetes Research and Clinical Practice: MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists
Publication in Nature Communications: The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis
EASL 2024: Improvements in MACK-3, a diagnostic test for active metabolic dysfunction-associated steatohepatitis, parallel response to lanifibranor therapy
AASLD 2023: Lanifibranor Reverses Insulin Resistance and Improves Glucose and Lipid Metabolism in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
AASLD 2023: Lanifibranor improves liver histology and markers of cardiometabolic health in patients with NASH independent of PNPLA3 genotype: a retrospective analysis of the NATIVE study
AASLD 2023: Lanifibranor-associated adiponectin increase correlates with improvement of histological and serum markers of NASH severity both in terms of activity and fibrosis
EASL 2023: Unraveling the individual contributions of the PPAR isotypes to the pan-PPAR agonist Lanifibranor-induced improvements of the vascular alterations and liver histology in a rat model of early NAFLD ​ ​
EASL 2023: The pan-PPAR agonist Lanifibranor improves increased portal pressure, endothelial dysfunction and liver histology in a rat model of early NAFLD​
ADA 2023: Lanifibranor Improves Markers of Cardiometabolic Health in Patients with NASH and Type 2 Diabetes, Correlated with Responses in Adiponectin Levels
AASLD 2021: Liver Sinusoidal Endothelial Cell (LSEC) capillarization in NASH and its evolution following lanifibranor treatment: an exploratory study of the NATIVE clinical trial
AASLD 2021: Lanifibranor treatment improves hepatic steatosis in patients with NASH, evaluated by histological grading and Controlled Attenuation Parameter (CAP)
Treatment of Mucopolysaccharidosis type VI patients with odiparcil alone or in addition to enzyme replacement therapy: a phase IIa study WORDSymposium 2020
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages Journal of Hepatology Sander Lefere, Tobias Puengel, Jana Hundertmark,., Lindsey Devisscher, Guillaume Wettstein, Frank Tacke
AASLD 2020 : Selection based on SAF Activity score instead of NASH CRN NAFLD Activity Score leads to selection of a more severe NASH with more advanced fibrosis patient cohort in the NATIVE phase 2b study of the panPPAR agonist Lanifibranor
AASLD 2020: Effect of the panPPAR agonist lanifibranor on plasma biomarkers of liver necroâ€inflammation and fibrosis in nonâ€cirrhotic NASH patients: additional results of the NA11 12TIVE Phase 2b trial.13
AASLD 2020: Efficacy of the panPPAR agonist lanifibranor on the histological endpoints NASH resolution and fibrosis regression is similar in typeâ€2 diabetic and nonâ€diabetic patients: additional results of the NATIVE Phase 2b trial in nonâ€cirrhotic NASH
Evidence for Altered Peroxisome Proliferator Activated Receptor (PPAR) Pathway Activity in a Transgenic Mouse Model of Scleroderma (TbetaRIIgammak-fib): Analysis of Mouse Skin, Lung and Explanted Cells
In vivo assessment of lung fibrosis’ prevention using the pan-PPAR agonist lanifibranor in the TbetaRIIgammak-fib (Transgenic Mouse Model of Scleroderma) mouse model of systemic sclerosis
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate
One Hour Pre-Infusion followed by Four Hours Co-Infusion of Elacridar as a Tool to Identify the Involvement of P-gp and BCRP in the Brain Penetration of Test Compounds in Rats
This medical affairs website is intended to support healthcare professionals with scientific information. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a healthcare professional.
You are leaving this site
This link will take you to a website that is outside the control of Inventiva. Links are provided as a courtesy for informational purposes only. We do not make or imply any endorsement of external websites.
ClinicalTrials.gov
